Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
Sònia Guedan(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Carl H. June(Parker Institute for Cancer Immunotherapy)
Cited by 573
Related Papers
CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
|Frontiers in Immunology|2020|310
Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses
|JCI Insight|2018|279
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma
|JCI Insight|2018|196
Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability
|Journal of Clinical Investigation|2020|195
Combined disruption of T cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cells
|Proceedings of the National Academy of Sciences|2023|77